FDA View of Cognitive Deficits in Schizophrenia as a Target for Drug Development

Problems with Pseudospecific Claim

•Serves only promotional purpose

•Implied advantage over other drugs in class regarding subgroup/symptom •Misleading (since no evidence to support)